{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:51:22Z","timestamp":1791820282587,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Illumina Accelerator UK","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is an androgen receptor (AR) driven, high-incidence disease significantly contributing to cancer mortality. To improve treatment outcomes for patients at high risk of metastasis, PCa is in need of better risk stratification at diagnosis. The unfolded protein response (UPR) is an AR-dependent process. However, the impact of the UPR transducer IRE1 on AR-dependent biology and acquired treatment resistance has not been defined. We use pre-clinical models of stress response to describe the impact of IRE1 activity loss on multiple PCa stages and demonstrate its involvement with poor prognosis (RB1 loss), and cell lineage determination (club-like phenotypes). Integrating clinical transcriptomic datasets, we chart IRE1 activity throughout PCa evolution and develop an IRE1 activity signature (IRE1sig1.0) reflecting both tumoral and micro-environmental stress responses. IRE1sig1.0 correlates with tumoral identity, and prognosticates localised and metastatic disease independently from AR activity. Using IRE1sig1.0 as a tool may inform ARSI suitability and guide IRE1 modulation as a novel combination therapeutic in prostate cancer.<\/jats:p>","DOI":"10.1038\/s44321-026-00490-w","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:01:13Z","timestamp":1787400073000},"page":"3898-3938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-9873","authenticated-orcid":false,"given":"Dimitrios","family":"Doultsinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Tomljanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Pilalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9588-5005","authenticated-orcid":false,"given":"Sophia M","family":"Abusamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alshalalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhula","family":"Ahire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen E","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Figiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-3849","authenticated-orcid":false,"given":"Joanna","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-4610","authenticated-orcid":false,"given":"Yanis","family":"Zekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":false,"given":"Charlotte L","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2968-7155","authenticated-orcid":false,"given":"Alastair D","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Macauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Phillipe","family":"Theurillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-3652","authenticated-orcid":false,"given":"Alfonso","family":"Urbanucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-7289","authenticated-orcid":false,"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-6054","authenticated-orcid":false,"given":"Clementine","family":"Le Magnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-0844","authenticated-orcid":false,"given":"Aristotelis","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-5083","authenticated-orcid":false,"given":"Ian G","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"490_CR2","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"166","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 166:11428\u201311436","journal-title":"Proc Natl Acad Sci USA"},{"key":"490_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/febs.14608","volume":"286","author":"A Almanza","year":"2019","unstructured":"Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Lu\u00eds A, McCarthy N, Montibeller L, More S et al (2019) Endoplasmic reticulum stress signalling \u2013 from basic mechanisms to clinical applications. FEBS J 286:241\u2013278","journal-title":"FEBS J"},{"key":"490_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-30159-0","volume":"13","author":"A Almanza","year":"2022","unstructured":"Almanza A, Mnich K, Blomme A, Robinson CM, Rodriguez-Blanco G, Kierszniowska S, McGrath EP, Le Gallo M, Pilalis E, Swinnen JV et al (2022) Regulated IRE1\u03b1-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer. Nat Commun 13:1\u201313","journal-title":"Nat Commun"},{"key":"490_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-83215-y","volume":"11","author":"F Amoroso","year":"2021","unstructured":"Amoroso F, Glass K, Singh R, Liberal F, Steele RE, Maguire S, Tarapore R, Allen JE, Van Schaeybroeck S, Butterworth KT et al (2021) Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. Sci Rep 11:1\u201316","journal-title":"Sci Rep"},{"key":"490_CR60","doi-asserted-by":"crossref","unstructured":"Anders S, Pyl PT, Huber W (2015) HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166\u2013169","DOI":"10.1093\/bioinformatics\/btu638"},{"key":"490_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298\u2013305","journal-title":"Nat Med"},{"key":"490_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN et al (2017) Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32:474","journal-title":"Cancer Cell"},{"key":"490_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26840-5","volume":"12","author":"M Bolis","year":"2021","unstructured":"Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Impellizzieri D, Di Rito L, Zoni E, Mosole S, Elia AR et al (2021) Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun 12:1\u201315","journal-title":"Nat Commun"},{"key":"490_CR9","first-page":"1","volume":"2026","author":"JP Bossowski","year":"2026","unstructured":"Bossowski JP, Pillai R, Kilian J, Wong Lau A, Nakamura M, Rashidfarrokhi A, Hao Y, Li R, Wu K, Hattori T et al (2026) The integrated stress response promotes immune evasion through lipocalin 2. Nature 2026:1\u201310","journal-title":"Nature"},{"key":"490_CR10","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/MCB.00013-15","volume":"35","author":"MD Bright","year":"2015","unstructured":"Bright MD, Itzhak DN, Wardell CP, Morgan GJ, Davies FE (2015) Cleavage of BLOC1S1 mRNA by IRE1 is sequence specific, temporally separate from XBP1 splicing, and dispensable for cell viability under acute endoplasmic reticulum stress. Mol Cell Biol 35:2186\u20132202","journal-title":"Mol Cell Biol"},{"key":"490_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/1878-0261.12354","volume":"12","author":"MM Centenera","year":"2018","unstructured":"Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P et al (2018) A patient-derived explant (PDE) model of hormone-dependent cancer. Mol Oncol 12:1608","journal-title":"Mol Oncol"},{"key":"490_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F et al (2021) Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol 23:87\u201398","journal-title":"Nat Cell Biol"},{"key":"490_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O et al (2019) Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7\u201318","journal-title":"Eur J Cancer"},{"key":"490_CR61","doi-asserted-by":"crossref","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15\u201321","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"490_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/febs.15372","volume":"288","author":"D Doultsinos","year":"2021","unstructured":"Doultsinos D, Carlesso A, Chintha C, Paton JC, Paton AW, Samali A, Chevet E, Eriksson LA (2021) Peptidomimetic-based identification of FDA-approved compounds inhibiting IRE1 activity. FEBS J 288:945\u2013960","journal-title":"FEBS J"},{"key":"490_CR15","doi-asserted-by":"publisher","unstructured":"Doultsinos D, McMahon M, Voutetakis K, Obacz J, Pineau R, Le Reste P-J, Obiedat A, Samal J, Patterson JB, Zheng Q et al (2019) Constitutive UPRER activation sustains tumor cell differentiation. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/594630","DOI":"10.1101\/594630"},{"key":"490_CR16","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/JME-20-0057","volume":"65","author":"D Doultsinos","year":"2020","unstructured":"Doultsinos D, Mills I (2020) The role of the androgen receptor as a driver and mitigator of cellular stress. J Mol Endocrinol 65:R19\u2013R33. 1","journal-title":"J Mol Endocrinol"},{"key":"490_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ebiom.2017.02.022","volume":"17","author":"MJ Dunning","year":"2017","unstructured":"Dunning MJ, Vowler SL, Lalonde E, Ross-Adams H, Boutros P, Mills IG, Lynch AG, Lamb AD (2017) Mining Human Prostate Cancer Datasets: The \u201ccamcAPP\u201d Shiny App. EBioMedicine 17:5","journal-title":"EBioMedicine"},{"key":"490_CR62","doi-asserted-by":"crossref","unstructured":"Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207\u2013210","DOI":"10.1093\/nar\/30.1.207"},{"key":"490_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","volume":"608","author":"A Erickson","year":"2022","unstructured":"Erickson A, He M, Berglund E, Marklund M, Mirzazadeh R, Schultz N, Kvastad L, Andersson A, Bergenstr\u00e5hle L, Bergenstr\u00e5hle J et al (2022) Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature 608:360\u2013367","journal-title":"Nature"},{"key":"490_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","volume":"7","author":"FY Feng","year":"2021","unstructured":"Feng FY, Huang HC, Spratt DE, Zhao S, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA et al (2021) Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the nrg\/rtog 9601 randomized clinical trial. JAMA Oncol 7:544","journal-title":"JAMA Oncol"},{"key":"490_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01863-2","volume":"22","author":"S Figiel","year":"2023","unstructured":"Figiel S, Yin W, Doultsinos D, Erickson A, Poulose N, Singh R, Magnussen A, Anbarasan T, Teague R, He M et al (2023) Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures. Mol Cancer 22:1\u20135","journal-title":"Mol Cancer"},{"key":"490_CR21","doi-asserted-by":"publisher","first-page":"818719","DOI":"10.3389\/fgene.2022.818719","volume":"13","author":"M Flores","year":"2022","unstructured":"Flores M, Goodrich DW (2022) Retinoblastoma protein paralogs and tumor suppression. Front Genet 13:818719","journal-title":"Front Genet"},{"key":"490_CR1","unstructured":"Genomics Resource for Intelligent Discovery (GRID) registry (ClinicalTrials.gov ID: NCT02609269). [DATASET]"},{"key":"490_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","volume":"34","author":"C Gerhauser","year":"2018","unstructured":"Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, H\u00fcbschmann D et al (2018) Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell 34:996\u20131011.e8","journal-title":"Cancer Cell"},{"key":"490_CR23","first-page":"1052","volume":"16","author":"JMD Grandjean","year":"2020","unstructured":"Grandjean JMD, Madhavan A, Cech L, Seguinot BO, Paxman RJ, Smith E, Scampavia L, Powers ET, Cooley CB, Plate L et al (2020) Pharmacologic IRE1\/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol 2020 16:10 16:1052\u20131061","journal-title":"Nat Chem Biol 2020 16:10"},{"key":"490_CR24","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.cell.2025.07.042","volume":"188","author":"E Grist","year":"2025","unstructured":"Grist E, Dutey-Magni P, Parry MA, Mendes L, Sachdeva A, Proudfoot JA, Hamid AA, Ismail M, Howlett S, Friedrich S et al (2025) Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell 188:5717\u20135734.e10","journal-title":"Cell"},{"key":"490_CR25","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"490_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","volume":"27","author":"MX He","year":"2021","unstructured":"He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM et al (2021) Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 27:426\u2013433","journal-title":"Nat Med"},{"key":"490_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K et al (2023) Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun 14:1\u201320","journal-title":"Nat Commun"},{"key":"490_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.6149","volume":"261","author":"FW Huang","year":"2023","unstructured":"Huang FW, Song H, Weinstein HNW, Xie J, Cooperberg MR, Hicks J, Mummert L, De Marzo AM, Sfanos KS (2023) Club-like cells in proliferative inflammatory atrophy of the prostate. J Pathol 261:85\u201395","journal-title":"J Pathol"},{"key":"490_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/path.5857","volume":"256","author":"DB Joseph","year":"2022","unstructured":"Joseph DB, Henry GH, Malewska A, Reese JC, Mauck RJ, Gahan JC, Hutchinson RC, Mohler JL, Roehrborn CG, Strand DW (2022) 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J Pathol 256:427\u2013441","journal-title":"J Pathol"},{"key":"490_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1126\/science.aay0267","volume":"368","author":"WR Karthaus","year":"2020","unstructured":"Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, Carver B, Gopalan A, Abida W, Laudone V et al (2020) Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science 368:497\u2013505","journal-title":"Science"},{"key":"490_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","volume":"22","author":"HL Kim","year":"2018","unstructured":"Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC et al (2018) Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis 22:399\u2013405","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"490_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, Salonen I, Spotbeen X, Giesen A, Parker CTA et al (2024) Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun 15:1\u201316","journal-title":"Nat Commun"},{"key":"490_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-690","volume":"14","author":"D Knezevic","year":"2013","unstructured":"Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA et al (2013) Analytical validation of the Oncotype DX prostate cancer assay \u2013 a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14:690","journal-title":"BMC Genomics"},{"key":"490_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labb\u00e9 DP, Gomez EC, Wang J et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78\u201383","journal-title":"Science"},{"key":"490_CR35","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, Da Costa RMG, Kaipainen A et al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest 129:4492","journal-title":"J Clin Invest"},{"key":"490_CR36","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/1878-0261.70065","volume":"19","author":"DA Leach","year":"2025","unstructured":"Leach DA, Chatterjee N, Spahr K, de Almeida GS, Varela-Carver A, Shah TT, Winkler M, Ahmed HU, Bevan CL (2025) Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis. Mol Oncol 19:2797\u20132821","journal-title":"Mol Oncol"},{"key":"490_CR37","doi-asserted-by":"publisher","first-page":"e7929","DOI":"10.15252\/emmm.201707929","volume":"10","author":"S Lhomond","year":"2018","unstructured":"Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F et al (2018) Dual IRE1 RNase functions dictate glioblastoma development. EMBO Mol Med 10:e7929","journal-title":"EMBO Mol Med"},{"key":"490_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/0008-5472.CAN-21-1159","volume":"82","author":"AC Mandigo","year":"2022","unstructured":"Mandigo AC, Shafi AA, McCann JJ, Yuan W, Laufer TS, Bogdan D, Gallagher L, Dylgjeri E, Semenova G, Vasilevskaya IA et al (2022) Novel oncogenic transcription factor cooperation in RB-deficient cancer. Cancer Res 82:221\u2013234","journal-title":"Cancer Res"},{"key":"490_CR39","doi-asserted-by":"publisher","first-page":"9794","DOI":"10.1126\/sciadv.abl9794","volume":"8","author":"C Miao","year":"2022","unstructured":"Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW et al (2022) RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv 8:9794","journal-title":"Sci Adv"},{"key":"490_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04130-7","volume":"22","author":"HE Miller","year":"2021","unstructured":"Miller HE, Bishop AJR (2021) Correlation AnalyzeR: functional predictions from gene co-expression correlations. BMC Bioinformatics 22:206","journal-title":"BMC Bioinformatics"},{"key":"490_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z et al (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer. Science 355:84\u201388","journal-title":"Science"},{"key":"490_CR42","doi-asserted-by":"publisher","first-page":"107669","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"MD Nyquist","year":"2020","unstructured":"Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J et al (2020) Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep 31:107669","journal-title":"Cell Rep"},{"key":"490_CR43","doi-asserted-by":"publisher","unstructured":"Parry M, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S et al (2023) Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2488586\/v1.","DOI":"10.21203\/rs.3.rs-2488586\/v1"},{"key":"490_CR44","doi-asserted-by":"publisher","first-page":"e2415308122","DOI":"10.1073\/pnas.2415308122","volume":"122","author":"SP Pitzen","year":"2025","unstructured":"Pitzen SP, Rudenick AN, Qiu Y, Zhang W, Munro SA, McCluskey BM, Forster C, Bergom HE, Ali A, Boytim E et al (2025) Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer. Proc Natl Acad Sci USA 122:e2415308122","journal-title":"Proc Natl Acad Sci USA"},{"key":"490_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63\u201389","journal-title":"World J Oncol"},{"key":"490_CR46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.trecan.2020.07.006","volume":"6","author":"DP Raymundo","year":"2020","unstructured":"Raymundo DP, Doultsinos D, Guillory X, Carlesso A, Eriksson LA, Chevet E (2020) Pharmacological targeting of IRE1 in cancer. Trends Cancer 6:1018\u20131030","journal-title":"Trends Cancer"},{"key":"490_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","volume":"23","author":"NL Sharma","year":"2013","unstructured":"Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et al (2013) The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in Man. Cancer Cell 23:35\u201347","journal-title":"Cancer Cell"},{"key":"490_CR48","doi-asserted-by":"publisher","first-page":"788","DOI":"10.15252\/emmm.201404509","volume":"7","author":"X Sheng","year":"2015","unstructured":"Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Waehre H et al (2015) Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Mol Med 7:788\u2013801","journal-title":"EMBO Mol Med"},{"key":"490_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08152-3","volume":"10","author":"X Sheng","year":"2019","unstructured":"Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS et al (2019) IRE1\u03b1-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun 10:323","journal-title":"Nat Commun"},{"key":"490_CR50","first-page":"1","volume":"2022 13","author":"H Song","year":"2022","unstructured":"Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY et al (2022) Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun 2022 13:1\u201320","journal-title":"Nat Commun"},{"key":"490_CR51","doi-asserted-by":"publisher","unstructured":"Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen Y-A, Weinstein HNW et al (2026) A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.03.25.711335","DOI":"10.64898\/2026.03.25.711335"},{"key":"490_CR52","doi-asserted-by":"crossref","unstructured":"Spratt D et al (2017) Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease, J Clin Oncol 35:1991\u20131998","DOI":"10.1200\/JCO.2016.70.2811"},{"key":"490_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/ERC-19-0181","volume":"27","author":"S Stelloo","year":"2020","unstructured":"Stelloo S, Linder S, Nevedomskaya E, Valle-Encinas E, de Rink I, Wessels LFA, van der Poel H, Bergman AM, Zwart W (2020) Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program. Endocr Relat Cancer 27:67\u201379","journal-title":"Endocr Relat Cancer"},{"key":"490_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11\u201322","journal-title":"Cancer Cell"},{"key":"490_CR55","unstructured":"TCGA data was accessed via the GDC Data Portal (https:\/\/portal.gdc.cancer.gov\/projects\/TCGA-PRAD, TCGA-PRAD.2022-04-27). [DATASET]"},{"key":"490_CR56","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/0008-5472.CAN-16-1589","volume":"77","author":"C Thangavel","year":"2017","unstructured":"Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P et al (2017) RB loss promotes prostate cancer metastasis. Cancer Res 77:982\u2013995","journal-title":"Cancer Res"},{"key":"490_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NCE, Mahadevan NR, Mizuno K, Puca L et al (2024) Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun 15:1\u201315","journal-title":"Nat Commun"},{"key":"490_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/1541-7786.MCR-23-0045","volume":"21","author":"VB Venkadakrishnan","year":"2023","unstructured":"Venkadakrishnan VB, Yamada Y, Weng K, Idahor O, Beltran H (2023) Significance of RB loss in unlocking phenotypic plasticity in advanced cancers. Mol Cancer Res 21:497","journal-title":"Mol Cancer Res"},{"key":"490_CR59","doi-asserted-by":"crossref","unstructured":"Welti J, Bogdan D, Figueiredo I, Coleman I, Jim\u00e9nez Vacas J, Liodaki K, Weigl F, Buroni L, Zeng W, Bernett I et al (2025) NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth. Clin Cancer Res 31:1109\u20131126","DOI":"10.1158\/1078-0432.CCR-24-2386"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00490-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:42:00Z","timestamp":1791819720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00490-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00490-w","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Pilalis and Prof Chatziioannou work for e-NIOS, Greece. Dr Alshalalfa and Dr Davicioni work for Veracyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}